Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Poland identifies two Ukrainian suspects in railway sabotage blast - 2NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- 3These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E
- 4'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- 5Significant Elements to Consider Prior to Applying for a Mastercard: 6 Vital Contemplations
- Sun storms are powered by a magnetic engine 16 Earths deep, study finds
- EU calls on Western Balkans to step up reforms for membership
- Scientists detect X-ray glow from interstellar comet 3I/ATLAS extending 250,000 miles into space
- Germany's Lufthansa enters race for stake in Portuguese airline TAP
- New movies to watch this weekend: See 'We Bury the Dead' in theaters, rent 'Wicked: For Good,' stream 'The Unbreakable Boy' on Starz
- 5 Wellbeing Applications Assist You With remaining Fit
- WHO suspends Gaza medical evacuations after contractor killed by Israeli troops
- Lightning on Jupiter could be up to 1 million times stronger than on Earth
- A Sweet Choice: Pick Your #1 Cake!
